Rocket Pharmaceuticals (RCKT) Other Accumulated Expenses (2014 - 2026)

Rocket Pharmaceuticals has disclosed Other Accumulated Expenses across 13 years of filings, most recently posting $4.2 million for Q1 2026.

• Other Accumulated Expenses for Q1 2026 came in at $4.2 million, up 43.4% year-over-year; the trailing twelve-month figure through Mar 2026 was $4.2 million (up 43.4% YoY), and the FY2025 annual result was $2.3 million, up 43.45% from the prior year.
• Other Accumulated Expenses came in at $4.2 million for Q1 2026 at Rocket Pharmaceuticals, up from $2.3 million in the prior quarter.
• In the past five years, Other Accumulated Expenses ranged from a high of $4.2 million in Q1 2026 to a low of $645000.0 in Q2 2022.
• The 5-year median for Other Accumulated Expenses is $1.9 million (2022), against an average of $2.1 million.
• Across the five-year window, Other Accumulated Expenses surged 371.58% in 2022 and sank 44.17% in 2025, its largest moves.
• Rocket Pharmaceuticals' Other Accumulated Expenses stood at $2.3 million in 2022, then retreated by 22.04% to $1.8 million in 2023, then decreased by 8.3% to $1.6 million in 2024, then soared by 43.45% to $2.3 million in 2025, then soared by 81.17% to $4.2 million in 2026.
• The last three Other Accumulated Expenses figures came in at $4.2 million (Q1 2026), $2.3 million (Q4 2025), and $2.7 million (Q3 2025), per Business Quant data.